Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy
Sponsor:
Yonsei University
Location:
Severance Hospital
Country:
South Korea This study is based on positive results in open label trial of mesenchymal stem cells therapy in patients with Multiple System Atrophy (MSA).
A Double-blind Placebo-controlled Randomized Clinical Trial.
Eligible Ages for Trial:
up to 75 Years
Eligible Genders for Trial:
Both
Illness:
Multiple System Atrophy (MSA) Inclusion Criteria:
- 75 Years Old or Less
- Multiple System Atrophy
- Voluntary Participants
Exclusion Criteria:
- Doubted dementia (MMSE < 24)
- Severe febrile condition
- Serum SGOT/SGPT three times above
- Malignant mass
November 1, 2009
Trial Status:
Recruiting Contact:
Philhyu Lee, MD, PhD 82-2228-1608 phlee@yuhs.ac
Print
Email page